Business Wire

Europastry and Blue Yonder Team Up To Strategically Drive Efficiency, Sustainability and Customer Satisfaction

Share

Global bakery leader implements Blue Yonder transportation management solutions supported by BlueGistics to optimize supply chain operations across Europe

Delivering frozen bakery products presents several challenges that can impact the efficiency, profitability and sustainability of the supply chain. To address these challenges, Europastry, a world leader in the frozen bakery industry, has selected Blue Yonder’s transportation management solutions to evolve its supply processes and optimize its logistics operations. The transformational project was deployed by BlueGistics, a Blue Yonder partner and worldwide consulting company specializing in the implementation of Transportation Management Systems.

With an ever-growing distribution network spanning more than 80 countries, Europastry sought to increase efficiency in its transportation processes, reduce costs, and continue delivering its wide range of bakery products efficiently. Blue Yonder’s transportation management solutions provide Europastry a comprehensive offering with real-time visibility into transportation operations, enabling the company to better plan and execute its deliveries. The solutions integrate advanced analytics and machine learning to optimize routes, reduce transit times, and enhance overall efficiency.

“Efficient transportation management is crucial to our ability to meet the high-quality standards our customers expect,” said Andreu Venteo Casas, global supply chain director, Europastry. “With Blue Yonder’s transportation management solutions, we will be able to streamline our logistics operations, ensuring that our products are delivered quickly and sustainably. This is a significant step towards optimizing our supply chain and reducing operational costs.”

As Europastry’s supply chain expands, managing transportation routes and ensuring timely deliveries across multiple regions becomes increasingly complex. Thanks to Blue Yonder’s transportation management solutions supported by BlueGistics, Europastry expects to achieve the following benefits:

  • Increase customer service levels and satisfaction by reducing lead times.
  • Improve profitability by reducing logistics costs.
  • Support sustainability goals by optimizing routes, reducing fuel consumption, and lowering carbon emissions.
  • Balance efficiency with supply chain agility and resilience to adapt to changing market conditions.

“In today’s complex supply chain environment, effective transportation management is more important than ever. We are thrilled to support Europastry in strategically transforming their supply chain operations,” said Terry Turner, president, Global Manufacturing, Blue Yonder. “With our transportation management solutions deployed by BlueGistics, Europastry will not only reduce transportation costs but also improve service levels for its customers, driving both operational excellence and sustainability.”

“By optimizing routes and reducing transportation costs, we’re empowering Europastry to meet growing customer demand while maintaining their commitment to sustainability. As Europastry continues its business expansion across Europe and beyond, we look forward to being a key partner in their journey, ensuring that their supply chain evolves alongside their success,” said Adrià Estañol, chief executive officer, BlueGistics.

Additional Resources:

About Europastry

Europastry is a family business specialized in frozen bakery. At our core, we are bakers ready to transform baking as we know it. Respecting and honouring the tradition of artisan baking is, along with our curious spirit and our tireless pursuit of innovation, the basis of all our work. Today, Europastry is present in more than 80 countries, through our more than 5,000 bakers, 27 production plants and 30 commercial offices. Europastry – We are bakers europastry.com

About BlueGistics

BlueGistics is a leading consulting firm specialized in Blue Yonder Transportation Management. As an official partner of Blue Yonder, we excel in delivering expert solutions for TMS implementation, support, rollouts, upgrades, migrations, and training. Our commitment to exceptional quality, service, and value ensures success in every project we undertake. BlueGistics – Futuring the Transportation bluegistics.com

About Blue Yonder

Blue Yonder is the world leader in digital supply chain transformation. Retailers, manufacturers and logistics service providers worldwide rely on Blue Yonder to optimize and accelerate their supply chain from planning through fulfilment, delivery, and returns. Blue Yonder’s AI-driven supply chain platform and multi-enterprise, multi-tier network enable more accurate forecasting and dynamic management of capacity, inventory and transport. Blue Yonder helps businesses navigate modern supply chain complexity and volatility with more resilient, sustainable supply chains to delight customers, scale profitably, and run flawlessly. www.blueyonder.com

“Blue Yonder” is a trademark or registered trademark of Blue Yonder Group, Inc. Any trade, product or service name referenced in this document using the name “Blue Yonder” is a trademark and/or property of Blue Yonder Group, Inc. All other company and product names may be trademarks, registered trademarks or service marks of the companies with which they are associated.

View source version on businesswire.com: https://www.businesswire.com/news/home/20250115369518/en/

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

CorriXR Therapeutics, InhaTarget Therapeutics, and Merxin Ltd Announce Strategic Collaboration for the Development of Inhaled Lung Cancer Treatment2.12.2025 14:30:00 CET | Press release

CorriXR Therapeutics, an oncology-focused biotherapeutics company pioneering a ground-breaking gene editing platform technology, InhaTarget Therapeutics, a company dedicated to the early development and clinical validation of innovative treatments of pulmonary diseases by inhalation, and Merxin Ltd, a designer and supplier of inhaler devices, have entered a strategic collaboration to develop a pioneering inhaled genetic therapy targeting lung cancer. The partnership draws upon CorriXR’s proprietary CRISPR-based gene editing platform targeting NRF2, InhaTarget’s proprietary formulation platform and strong experience in pulmonary drug development, and Merxin Ltd’s advanced inhalation device technology. Through their combined expertise, they aim to create a patient-friendly inhaled therapy that delivers targeted treatment directly to lung tumors, maximizing efficacy, minimizing systemic side effects, and offering new hope for patients facing one of the world’s deadliest cancers. Innovativ

Aurigene Oncology Limited Announces Encouraging Initial Data From 1st Two Cohorts of Phase 1 Study of AUR112, an Oral Small Molecule Inhibitor of MALT1, in Relapsed/Refractory Lymphoid Malignancies2.12.2025 14:00:00 CET | Press release

Aurigene Oncology Limited, a clinical-stage biopharmaceutical company developing novel therapies in oncology,today announced initial clinical results from 1st two cohorts of its ongoing Phase 1 clinical trial evaluating AUR112 in patients with relapsed or refractory lymphoid malignancies. Early findings show that AUR112 is safe, well tolerated, demonstrating meaningful clinical activity, with objective responses observed across multiple lymphoma subtypes, including Mantle Cell Lymphoma (MCL) and Marginal Zone Lymphoma (MZL). “We are very encouraged by the early results of the first two cohorts from our Phase 1 study of AUR112,” said Dr. Murali Ramachandra, CEO. “AUR112 has shown a promising initial clinical profile, achieving an overall response rate of 63.6% in the efficacy-evaluable population and 58.3% in the intent-to-treat group. These strong early data, combined with its distinct preclinical and safety characteristics, reinforce our belief that AUR112 has the potential to become

AdvanCell Initiates Phase 2 Expansion Trial of ADVC001, a Novel Targeted Alpha Therapy for Prostate Cancer2.12.2025 14:00:00 CET | Press release

Clinical development of 212Pb-ADVC001 (ADVC001) is advancing rapidly with encouraging Phase 1b data presented at ESMO 2025 The Phase 2 expansion will evaluate 160 MBq and 200 MBq doses of ADVC001 using a randomized, multi-dose-response design and adaptive dosing strategies to optimize clinical outcomes across three indications: metastatic hormone-sensitive prostate cancer (mHSPC) and metastatic castration-resistant prostate cancer (mCRPC) in pre-chemotherapy and post-177Lu-PSMA radioligand therapy (RLT) settings AdvanCell, a clinical-stage radiopharmaceutical company developing innovative targeted alpha therapies for cancer, today announced the initiation of the TheraPb Phase 2 expansion trial (NCT05720130) evaluating its lead investigational candidate, ADVC001, in metastatic prostate cancer. The news follows the encouraging Phase 1b dose escalation results presented at the European Society for Medical Oncology (ESMO) 2025 congress that showed a favorable safety profile and compelling

Luma AI Opens for International Business With Former WPP Executive Jason Day Leading New London Office2.12.2025 14:00:00 CET | Press release

Establishment of the London office follows Luma AI’s $900 million Series C investment led by HUMAIN - marking the company’s first major step towards international scale with plans to deepen partnerships across the UK, European Union, and Saudi Arabia in the first phase of expansion.Former Monks and WPP executive Jason Day was appointed Head of EMEA to launch Luma AI internationally and drive worldwide growth across creative, advertising, gaming, and entertainment sectors.Luma AI plans to add 200 new jobs in London in 2026. Luma AI, the frontier artificial intelligence company building multimodal AGI intelligence and known for its flagship product Dream Machine, today announced a major step in its global expansion with the opening of its first international office in London, UK. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251202217704/en/ LUMA AI OPENS FOR INTERNATIONAL BUSINESS WITH FORMER WPP EXECUTIVE JASON DAY LEADING

Eventbrite Enters into Definitive Agreement to Be Acquired by Bending Spoons for Roughly $500 Million to Accelerate Eventbrite’s Next Phase of Growth2.12.2025 13:30:00 CET | Press release

Eventbrite stockholders to receive $4.50 per share in cash Eventbrite, Inc. (NYSE: EB), the leading global marketplace for shared experiences, announced today that it has entered into a definitive agreement to be acquired by Bending Spoons, in an all-cash transaction valued at approximately $500 million. The acquisition is subject to customary closing conditions and approvals, including regulatory approvals and approval by Eventbrite’s stockholders. “For two decades, Eventbrite has stood at the forefront of the experience economy, helping tens of millions to create, discover, and attend unforgettable events,” said Luca Ferrari, Bending Spoons CEO and Co-Founder. “Joining forces with Bending Spoons will accelerate innovation and strengthen Eventbrite’s tools and resources to bring even more people together through shared live experiences for many years to come. As longstanding fans, we’ve identified a few opportunities that we’re excited about exploring with the Eventbrite team after cl

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye